Cite
HARVARD Citation
Usmani, S. et al. (2022). Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet oncology. 23 (1), pp. 65-76. [Online].